Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: FK463 Clear all
Terminated Phase 3 Interventional Results available

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

NCT05178862
View directory record Official record
Conditions
Candidiasis, Invasive, Candidemia
Interventions
SCY-078, Fluconazole, Echinocandin
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 3:38 AM EDT
Completed No phase listed Observational

PEACE: Pediatric Antifungal Comparative Effectiveness

NCT01869829
View directory record Official record
Conditions
Pediatric Invasive Candidiasis
Interventions
Observational antifungal therapy
Drug
Lead sponsor
Duke University
Other
Eligibility
120 Days to 18 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
27
States / cities
Little Rock, Arkansas • Orange, California • Palo Alto, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 23, 2026, 3:38 AM EDT
Terminated Phase 3 Interventional

Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU

NCT00048750
View directory record Official record
Conditions
Invasive Fungal Infections
Interventions
Micafungin, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
16 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
41
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2012 · Synced Oct 23, 2026, 3:38 AM EDT
Withdrawn Phase 4 Interventional

A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis

NCT00423163
View directory record Official record
Conditions
Aspergillosis/Blood, Aspergillosis/Invasive
Interventions
micafungin, voriconazole
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
44
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2015 · Synced Oct 23, 2026, 3:38 AM EDT
Completed Phase 1 Interventional

Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

NCT00607763
View directory record Official record
Conditions
Invasive Candidiasis, Esophageal Candidiasis, Oropharyngeal Candidiasis, Candidemia
Interventions
Micafungin (Mycamine)
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
4 Months to 23 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Los Angeles, California • Orange, California • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 23, 2026, 3:38 AM EDT
Completed No phase listed Observational Results available

Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia

NCT00723073
View directory record Official record
Conditions
Febrile Neutropenia
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2010 · Synced Oct 23, 2026, 3:38 AM EDT
Terminated Phase 2 Interventional

Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis

NCT00047827
View directory record Official record
Conditions
Aspergillosis
Interventions
Micafungin, Liposomal Amphotericin B
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 23, 2026, 3:38 AM EDT
Completed No phase listed Observational

Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents

NCT01686607
View directory record Official record
Conditions
Systemic Fungal Infections
Interventions
Parenteral micafungin application, Other parenteral antifungal drugs
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
Not listed
Enrollment
40,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
6
States / cities
Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 23, 2026, 3:38 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins

NCT00839540
View directory record Official record
Conditions
Candidemia
Interventions
Micafungin, Caspofungin
Drug
Lead sponsor
Gary E. Stein, Pharm.D.
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 23, 2026, 3:38 AM EDT
Withdrawn Phase 2 Interventional

Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis

NCT01207128
View directory record Official record
Conditions
Aspergillosis
Interventions
Voriconazole, micafungin
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Oct 23, 2026, 3:38 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Micafungin in Children on Extracorporeal Membrane Oxygenation

NCT01666769
View directory record Official record
Conditions
Invasive Candidiasis
Interventions
Micafungin
Drug
Lead sponsor
Kevin Watt
Other
Eligibility
Up to 18 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 23, 2026, 3:38 AM EDT
Completed Phase 4 Interventional Results available

Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome

NCT01200355
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
micafungin, posaconazole
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 23, 2026, 3:38 AM EDT
Completed Phase 1 Interventional

Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia

NCT00001790
View directory record Official record
Conditions
Fever, Mycoses, Neutropenia
Interventions
FK463
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 3:38 AM EDT
Terminated Phase 1 Interventional

Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease

NCT01950507
View directory record Official record
Conditions
Stem Cell Transplantation, Graft vs Host Disease
Interventions
Budesonide, Fluconazole, Voriconazole, Micafungin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
13 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 23, 2026, 3:38 AM EDT
Completed Phase 1 Interventional

Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

NCT00608335
View directory record Official record
Conditions
Oropharyngeal Candidiasis, Candidemia, Invasive Candidiasis, Esophageal Candidiasis
Interventions
Micafungin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
2 Years to 16 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Los Angeles, California • Orange, California • Kansas City, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 23, 2026, 3:38 AM EDT
Completed Phase 3 Interventional

Study of Micafungin in Patients With Invasive Candidiasis or Candidemia

NCT00105144
View directory record Official record
Conditions
Candidiasis, Candidemia
Interventions
Micafungin, Caspofungin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
62
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 23, 2026, 3:38 AM EDT
Completed Phase 3 Interventional

Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia

NCT00106288
View directory record Official record
Conditions
Candidiasis
Interventions
Micafungin, Liposomal Amphotericin B
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
Not listed
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
27
States / cities
Birmingham, Alabama • Orange, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 23, 2026, 3:38 AM EDT
Completed Phase 3 Interventional

Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients

NCT00001937
View directory record Official record
Conditions
Aspergillosis, Candidiasis, Fungemia, Mycoses
Interventions
FK463, Fluconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 3:38 AM EDT
Completed Phase 1 Interventional

An Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates

NCT00818584
View directory record Official record
Conditions
Candida
Interventions
Micafungin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
48 Hours to 120 Days
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
7
States / cities
Birmingham, Alabama • Orange, California • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Oct 23, 2026, 3:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug Concentration Analysis of Micafungin in Overweight, Obese, and Extremely Obese Volunteers

NCT01090141
View directory record Official record
Conditions
Obesity, Nutrition Disorders, Overweight
Interventions
Micafungin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 23, 2026, 3:38 AM EDT
Terminated Phase 1 Interventional

A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis

NCT02057289
View directory record Official record
Conditions
Immunocompromised, Bone Marrow Transplant, Cancer
Interventions
Micafungin
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Months to 10 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 23, 2026, 3:38 AM EDT
Terminated Phase 1 Interventional

Micafungin Lock Therapy

NCT00809887
View directory record Official record
Conditions
Catheter-Related Fungal Infections
Interventions
Micafungin lock therapy
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
6 Months to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2008 · Synced Oct 23, 2026, 3:38 AM EDT
Not yet recruiting No phase listed Observational

A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia

NCT06907992
View directory record Official record
Conditions
Candidemia
Interventions
Antifungal treatment
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 23, 2026, 3:38 AM EDT
Completed Phase 1 Interventional

A Study of Safety and Pharmacokinetics of Repeated Dose of Micafungin as Antifungal Prophylaxis in Children and Adolescents Who Undergo Hematopoietic Stem Cell Transplant

NCT00606268
View directory record Official record
Conditions
Fungal Infections
Interventions
Micafungin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
4 Months to 16 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 23, 2026, 3:38 AM EDT